Canada markets closed
  • S&P/TSX

    20,383.77
    +39.70 (+0.20%)
     
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • DOW

    34,347.03
    +152.97 (+0.45%)
     
  • CAD/USD

    0.7478
    -0.0021 (-0.28%)
     
  • CRUDE OIL

    76.28
    -1.66 (-2.13%)
     
  • BTC-CAD

    22,162.51
    -204.92 (-0.92%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • GOLD FUTURES

    1,754.00
    +8.40 (+0.48%)
     
  • RUSSELL 2000

    1,869.19
    +5.67 (+0.30%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • NASDAQ

    11,226.36
    -58.96 (-0.52%)
     
  • VOLATILITY

    20.50
    +0.08 (+0.39%)
     
  • FTSE

    7,486.67
    +20.07 (+0.27%)
     
  • NIKKEI 225

    28,283.03
    -100.06 (-0.35%)
     
  • CAD/EUR

    0.7186
    -0.0015 (-0.21%)
     

Zacks.com featured highlights include Terns Pharmaceuticals, Napco Security Technologies and AVEO

For Immediate Release

Chicago, IL – September 21, 2022 – Stocks in this week’s article are Terns Pharmaceuticals, Inc. TERN, Napco Security Technologies, Inc. NSSC and AVEO Pharmaceuticals, Inc. AVEO.

New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy

As Wall Street is reeling under the evolving geopolitical situation, Fed’s rate hikes and high inflation this year, investors are increasingly becoming thoughtful about choosing stocks for their portfolio.

As stock markets have been experiencing volatility, investors may look for stocks that recently received new analyst coverage. The logic behind this is that analysts don’t add a stock to their coverage randomly. New coverage on a stock is usually the result of a huge investor focus on it or its promising prospects.

Terns Pharmaceuticals, Inc., Napco Security Technologies, Inc. and AVEO Pharmaceuticals, Inc. are a few stocks that have witnessed new analyst coverage lately. These, therefore, are expected to attract investor attention.

There’s no denying that the lack of consistency in information creates inefficiencies that might result in misinterpretation of stocks. Initiation of coverage by analysts offers critical information on a stock which is of great value to investors.

Coverage initiation on a stock by analyst(s) usually depicts increased investor inclination. Investors, on their part, often assume that there is something in the stock that has attracted analyst attention. In other words, they believe that the company coming under the radar definitely has some value, which can be tapped into.

Obviously, stocks are not arbitrarily chosen to cover. New coverage on a stock usually reflects an encouraging future envisioned by the analyst(s). At times, increased investor focus on a stock motivates analysts to take a closer look at it.

Needless to say, the average change in broker recommendation is preferred over a single recommendation change.

How Does Analyst Coverage Influence Stock Price?

The price movement of a stock is generally a function of the recommendations on it from new analysts. Stocks typically see an upward price movement with a new analyst coverage compared to what they witness with a rating upgrade under an existing coverage. Positive recommendations – Buy and Strong Buy – generally lead to a significantly positive price reaction than a Hold recommendation. On the contrary, analysts hardly initiate coverage with a Strong Sell or Sell recommendation.

Now, if an analyst gives a new recommendation on a company that has limited or no existing coverage, investors start paying more attention to it. Also, any new information attracts portfolio managers to build a position in the stock.

So, it’s a good strategy to bet on stocks that have seen increased analyst coverage over the last few weeks.

Below, we have selected three stocks that have seen increased analyst coverage over the last few weeks and carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Here are three out of the 13 stocks that passed the screen:

Terns Pharmaceuticals: This is a clinical-stage biopharmaceutical company based in Foster City, CA. Terns Pharmaceuticals engages in the development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity.

TERN stock has gained 16% over the past six months against the industry’s 12.2% decline. Loss estimates for 2022 have narrowed to $2.10 per share from $2.18 over the past seven days. The estimated figure calls for a 5% improvement from the year-ago period.

Napco Security Technologies: Based in Amityville, NY, Napco Security engages in the development, manufacturing and selling of electronic security products in the United States and abroad.

NSSC stock has gained 44% over the past six months against the industry’s 16.7% decline. Earnings estimates for fiscal 2023 have increased to 71 cents per share from 52 cents over the past 30 days. The estimated figure calls for a 65.1% increase from the year-ago period.

AVEO Pharmaceuticals: This Boston, MA-based biopharmaceutical company develops and commercializes medicines for cancer patients.

AVEO stock has gained 42.9% over the past six months, outperforming the industry’s 12.1% decline. Loss estimates for 2022 have narrowed to 94 cents per share from $1.06 over the past 60 days. The estimated figure calls for a 42.3% improvement from the year-ago period.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/1982520/new-analysts-initiate-coverage-3-top-ranked-stocks-to-buy

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://www.twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AVEO Pharmaceuticals, Inc. (AVEO) : Free Stock Analysis Report
 
NAPCO Security Technologies, Inc. (NSSC) : Free Stock Analysis Report
 
Terns Pharmaceuticals, Inc. (TERN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research